|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 295 GBX | 0.00% |
|
-6.35% | -16.31% |
| Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
| Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
MaxCyte, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 15.67 million compared to USD 12.42 million a year ago. Net loss was USD 5.28 million compared to USD 4.81 million a year ago.
Basic loss per share from continuing operations was USD 0.05 compared to USD 0.05 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -16.31% | 384M | |
| +9.00% | 219B | |
| +7.35% | 183B | |
| +11.26% | 133B | |
| +25.25% | 108B | |
| +0.27% | 63.06B | |
| +12.47% | 52.02B | |
| -0.62% | 48.2B | |
| +0.04% | 40.37B | |
| +13.22% | 39.35B |
MAXCYTE, INC. 
